Developing game changing treatments and cell therapies for severe diseases

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

MORE ABOUT US

“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”

Professor Ann Logan,
Scientific Director, Neuregenix Ltd.

NEWS

5 July 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating…
Read More
5 July 2018
ILB – A game changer in Glaucoma
Viken, May 22nd, 2018 TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for…
Read More
5 June 2018
Anders Kristensson appointed CEO of TikoMed
Viken – 18th June 2018 TikoMed, a privately-held biopharmaceutical company today announced the appointment of…
Read More
27 April 2018
TIKOMED IS INTERVIEWED BY RAPIDUS
TikoMed fyller kassan inför ALS-studier 2018-04-23 Läkemedelsbolaget TikoMed från skånska Viken fyller på kassan med…
Read More

EVENTS

TIKOMED WILL BE SENDING TEAM TO BIO-EUROPE
Date: 5 November 2018 - 7 November 2018
Venue: Bella Center
Read More
MORE NEWS & EVENTS

SUBSCRIBE